LOGIN  |  REGISTER
Chimerix

MultiPlan Announces Participation at Upcoming Conferences

November 16, 2023 | Last Trade: US$14.69 0.09 -0.61

NEW YORK / Nov 16, 2023 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in person at the following conferences in November 2023:

  • Bank of America Leverage Finance Conference – Tuesday, November 28, 2023, at the Boca Raton Resort – Boca Raton, FL
  • 35th Annual Piper Sandler Healthcare Conference – Wednesday, November 29, 2023, at the Lotte New York Palace – New York, NY

A live webcast and audio archive of the events, if available, may be accessed through the investor relations section of MultiPlan’s website at investors.multiplan.us/events-and-presentations.

About MultiPlan

MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payors in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB